Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19
Sponsor: Rokote Laboratories Finland Oy
Summary
This is a Phase 1a, single-country, single-centre, single-blinded, COV2 vaccine formulation randomized trial designed to investigate and compare the safety and immunogenicity of two COV2 vaccine formulations. COV2 is a nasal, investigational vaccine against COVID-19, based on a serotype 5 adenoviral vector producing modified SARS-CoV-2 spike protein. Participants will receive one of the two COV2 formulations in two doses on Day 0 and Day 28. This trial consists of two parts; Part 1 is a vaccination phase assessing safety and immunogenicity and Part 2 is a long-term immunogenicity follow-up assessing persistence of immune response.
Official title: A Phase 1a, Single-Blind, Randomized Comparative Clinical Trial Evaluating the Impact of Vaccine Formulation on the Safety and Immunogenicity of the COV2 Vaccine in Healthy Adults
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2026-02-10
Completion Date
2026-11
Last Updated
2026-02-20
Healthy Volunteers
Yes
Conditions
Interventions
COVID-19 Vaccines
COV2 vaccine given in formulation A in 2 doses as a nasal spray, 28 days between each dose.
COVID-19 Vaccines
COV2 vaccine given in formulation B in 2 doses as a nasal spray, 28 days between each dose.
Locations (1)
Kuopio University Hospital, ENT policlinic
Kuopio, Northern Savonia, Finland